ethal injury to the heart can be dramatically blunted by brief periods of prior ischemia. 1 Such an endogenous cardioprotective mechanism, known as ischemic preconditioning (IPC), exists in all species examined to date, including humans. 2 IPC occurs in a biphasic pattern of myocardial protection: an early phase (classic IPC), which develops immediately and lasts approximately 2 hours after the IPC stimulus, and a delayed phase (late IPC or second window of protection), which reappears after 24 hours and lasts at least 72 hours. 3, 4 Despite intensive investigation, the cellular mechanism of IPC still remains obscure, although important clues are beginning to emerge.
A number of substances and signaling pathways have been proposed to be involved in mediating the cardioprotective effect of IPC (reviewed in Downey and Cohen 5 ). Nevertheless, considerable evidence has suggested that ATP-sensitive K ϩ (K ATP ) channels may serve as the end effectors in this process. 6 Although the cardioprotective effects were initially attributed to plasma membrane K ATP channels, the degree of action potential shortening can be divorced from the extent of protection. 7, 8 Instead, it now seems much more likely that K ATP channels in mitochondrial inner membrane (mitoK ATP channels) are the dominant players. The studies of the mitoK ATP channel were facilitated by the identification of a selective opener and a selective blocker of mitoK ATP channels (selective relative to cardiac sarcolemmal K ATP channels, by at least three orders of magnitude), namely diazoxide and 5-hydroxydecanoate. 9, 10 The mitoK ATP channel opener diazoxide mimics the infarct size-limiting effects of classic IPC, whereas the mitoK ATP channel blocker 5-hydroxydecanoate obliterates the beneficial effects of conditioning ischemia. 9, 11 Thus, mitoK ATP channels have emerged as the likely effectors of classic IPC.
The underlying pathophysiology and mechanisms between early and delayed phases of cardioprotection are likely to differ, with posttranslational modifications dominating the early phase; given the timing, changes in gene expression should only come to play in the delayed phase. Interestingly, the mitoK ATP channel now appears to feature prominently in both phases of protection. Bernardo et al 12 have reported that the mitoK ATP channel blocker 5-hydroxydecanoate abolishes late IPC in the rabbit heart. Fryer et al 13 also found that opioid-induced delayed protection in the rat heart was lost by 5-hydroxydecanoate. Moreover, in this issue of Circulation Research, Takashi et al 14 report that the mitoK ATP channel opener diazoxide mimics late IPC and reduces the infarct size after 24 hours in rat hearts. These studies suggest that mitoK ATP channels may be the site of action responsible for the cardioprotective effect of late IPC.
The study by Takashi et al 14 demonstrated that chelerythrine, a potent protein kinase C (PKC) inhibitor, abolished the diazoxide-induced delayed protection, suggesting that the mitoK ATP channel induces late IPC via PKC-mediated signaling pathway. The links between PKC and mitoK ATP channels were previously addressed by Sato et al, 10 in which exposure to phorbol 12-myristate 13-acetate, an activator of PKC, potentiated and accelerated the diazoxide-induced opening of mitoK ATP channels. Therefore, it is now apparent that activation of PKC figures prominently in the signal transduction cascade of both early and late phases of IPC. IPC causes isozyme-selective translocation of PKC. Although, in the present study, Takashi et al 14 did not identify the PKC isozyme responsible for the PKC-mitoK ATP channel signaling pathway, Wang and Ashraf 15 recently reported that PKC-␦ is translocated to mitochondria in rat myocytes. However, in another study, PKC-⑀ but not PKC-␦ has been argued to be responsible for the early phase of IPC in rabbit cardiomyocytes. 16 Further studies are still necessary to determine the similarity or difference concerning PKC isozymes responsible for the activation of the mitoK ATP channel in classic versus late IPC.
Bolli et a1 17 have addressed a possible role for nitric oxide (NO) in mediating late IPC. In this issue of Circulation Research, Dawn et al 18 demonstrate that protein tyrosine kinase is necessary to trigger and to mediate late IPC against myocardial stunning. Moreover, they show that protein tyrosine kinase signaling is essential for the augmentation of inducible NO synthase (iNOS) activity during the late phase of IPC, indicating that iNOS is involved as a downstream element of protein tyrosine kinase. Protein tyrosine kinase is reported to be downstream of protein kinase C for classic as well as late IPC in rabbits. 19, 20 It remains unknown whether PKC directly activates mitoK ATP channels or does so indirectly through a tyrosine kinase-mediated pathway. How might NO interact with mitoK ATP channels? New links between NO and these candidate effectors are reported by Sasaki et al, 21 who demonstrated that exposure of myocytes to an NO donor directly activates mitoK ATP channels as well as potentiates the ability of diazoxide to open these channels.
These findings, taken together, provide tangible links among various key elements in the late IPC cascade and implicate mitoK ATP channels as the effectors of late IPC.
The question remains as to how the opening of mitoK ATP channels might protect myocytes against ischemic damage. It has been proposed that membrane depolarization produced by the K ϩ entry may reduce mitochondrial Ca 2ϩ entry through the calcium uniport, which results in a reduction in mitochondrial Ca 2ϩ overload. Consistent with this hypothesis, mitoK ATP channel openers release Ca 2ϩ from Ca 2ϩ -loaded mitochondria. 22 Among the more interesting findings in the study by Takashi et al 14 was the antiapoptotic effect of diazoxide. They demonstrated that diazoxide decreased cell death by apoptosis, an effect that was antagonized by 5-hydroxydecanoate. In agreement with this study, it has been reported that IPC reduces ischemic injury by decreasing apoptosis in rat hearts. 23 Conversely, Holmuhamedov et al 22 reported that, in isolated cardiac mitochondria, the mitoK ATP channel opening by cromakalim and pinacidil increased matrix volume and released cytochrome c, which may counteract the postulated beneficial action of the mitoK ATP channel. These disparate results need to be reconciled in future studies. Perhaps crucial aspects of the apoptotic signaling pathways are disrupted in the process of mitochondrial isolation, in which case complementary studies on intact cells would be valuable.
Evidence is rapidly accumulating that the mitoK ATP channel may be the end effector responsible for cardioprotection in both early and late phases of IPC. Future studies of mitoK ATP channels are essential in elucidating just how activation of these channels protects against lethal injury in both the early and the delayed phases of IPC.
